Abstract
Background: In the primary analysis of the HER2CLIMB trial, tucatinib added to trastuzumab and capecitabine significantly improved overall survival (OS) and progression-free survival (PFS) in patients with human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer. We report efficacy and safety outcomes, including the final OS and safety outcomes from follow-up in HER2CLIMB. Patients and methods: HER2CLIMB is a randomized, double-blind, placebo-controlled trial in patients with locally advanced or metastatic HER2+ breast cancer, including patients with brain metastases. Patients were randomized 2 : 1 to receive tucatinib or placebo, in combination with trastuzumab and capecitabine. After the primary analysis (median follow-up of 14 months), the protocol was amended to allow for unblinding sites to treatment assignment and cross-over from the placebo combination to the tucatinib combination. Protocol prespecified descriptive analyses of OS, PFS (by investigator assessment), and safety were carried out at ∼2 years from the last patient randomized. Results: Six hundred and twelve patients enrolled in the HER2CLIMB trial. At a median OS follow-up of 29.6 months, median duration of OS was 24.7 months for the tucatinib combination group versus 19.2 months for the placebo combination group [hazard ratio (HR) for death: 0.73, 95% confidence interval (CI): 0.59-0.90, P = 0.004] and OS at 2 years was 51% and 40%, respectively. HRs for OS across prespecified subgroups were consistent with the HR for the overall study population. Median duration of PFS was 7.6 months for the tucatinib combination group versus 4.9 months for the placebo combination group (HR for progression or death: 0.57, 95% CI: 0.47-0.70, P < 0.00001) and PFS at 1 year was 29% and 14%, respectively. The tucatinib combination was well tolerated with a low rate of discontinuation due to adverse events. Conclusions: With additional follow-up, the tucatinib combination provided a clinically meaningful survival benefit for patients with HER2+ metastatic breast cancer.
Original language | English (US) |
---|---|
Pages (from-to) | 321-329 |
Number of pages | 9 |
Journal | Annals of Oncology |
Volume | 33 |
Issue number | 3 |
DOIs | |
State | Published - Mar 2022 |
Keywords
- brain metastases
- capecitabine
- human epidermal growth factor receptor 2-positive (HER2)
- metastatic breast cancer
- trastuzumab
- tucatinib
ASJC Scopus subject areas
- Hematology
- Oncology
Fingerprint
Dive into the research topics of 'Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Annals of Oncology, Vol. 33, No. 3, 03.2022, p. 321-329.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB)
T2 - final overall survival analysis
AU - Curigliano, G.
AU - Mueller, V.
AU - Borges, V.
AU - Hamilton, E.
AU - Hurvitz, S.
AU - Loi, S.
AU - Murthy, R.
AU - Okines, A.
AU - Paplomata, E.
AU - Cameron, D.
AU - Carey, L. A.
AU - Gelmon, K.
AU - Hortobagyi, G. N.
AU - Krop, I.
AU - Loibl, S.
AU - Pegram, M.
AU - Slamon, D.
AU - Ramos, J.
AU - Feng, W.
AU - Winer, E.
N1 - Funding Information: We thank the patients who participated in the HER2CLIMB trial and their families, as well as the investigators and research staff at all HER2CLIMB clinical sites; the members of the independent data and safety monitoring committee and the independent review committee; Gerald Engley, PharmD, Seagen Inc. for critical review and revision of the manuscript; and Wendi Schultz, MS, and Holly Tomlin, MPH, of Seagen Inc. and Laurie LaRusso, MS, of Chestnut Medical Communications for writing support, funded by Seagen Inc. This work was supported by Seagen Inc. (Bothell, WA, USA), the manufacturer of tucatinib and Merck Sharp & Dohme Corp. a subsidiary of Merck & Co. Inc. Kenilworth, NJ, USA (no grant number). Writing assistance was funded by Seagen Inc. in accordance with Good Publications Practice guidelines (no grant number). GC: consultancy with Bristol-Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Foundation Medicine, GlaxoSmithKline, Lilly, Novartis, Pfizer, Roche/Genentech, Samsung, and Seagen Inc.; honoraria from Ellipses Pharma; research funding/grants from Merck; speaker's bureau with Daiichi Sankyo, Foundation Medicine, Lilly, Novartis, Pfizer, Roche/Genentech, Samsung, and Seagen Inc.; travel from Pfizer and Roche/Genentech. VM: consultancy with Amgen, Daiichi Sankyo, Eisai, Gilead, Hexal, Lilly, Nektar, Roche, and Seagen Inc.; honoraria from Amgen, AstraZeneca, Daiichi Sankyo, Eisai, Genomic Health, Lilly, MSD Oncology, Nektar, Novartis, Onkowissen, Pfizer, Pierre Fabre, Roche, Seagen Inc. Tesaro, and Teva; speaker's bureau with Novartis, Roche, and Seagen Inc.; travel from Daiichi Sankyo, P Value Communications, and Roche. VB: consultancy with Seagen Inc.; research funding/grants from AstraZeneca, Genentech, Olema Oncology, Oncosec, Pfizer, and Seagen Inc. EH: consultancy with Genentech/Roche, Boehringer Ingelheim, Novartis, Dantari, Lilly, Merck, Puma Biotechnology, Silverback Therapeutics, CytomX, Pfizer, Mersana, Black Diamond, H3 Biomedicine, Daiichi Sankyo, AstraZeneca, Arvinas, Deciphera Pharmaceuticals, Eisai, and Seagen Inc.; research funding/grants from OncoMed, Genentech/Roche, Zymeworks, Rgenix, ArQule, Clovis, Silverback Therapeutics, Millennium, Acerta Pharma, Sermonix Pharmaceuticals, Torque, Black Diamond, Karyopharm, Infinity Pharmaceuticals, Curis, Syndax, Novartis, Boehringer Ingelheim, Immunomedics, FujiFilm, Taiho, Deciphera, Fochon, Molecular Templates, Onconova Therapeutics, Dana Farber Cancer Hospital, Hutchinson MediPharma, MedImmune, Seagen Inc. Puma Biotechnology, Compugen, TapImmune, Lilly, Pfizer, H3 Biomedicine, Takeda, Merus, Regeneron, Arvinas, Stemcentrx, Verastem, eFFECTOR Therapeutics, CytomX, InventisBio, Lycera, Mersana, Radius Health, AbbVie, Nucana, Leap Therapeutics, Zenith Epigenetics, Harpoon, Orinove, AstraZeneca, Tesaro, Macrogenics, EMD Serono, Daiichi Sankyo, Syros, Sutro, G1 Therapeutics, Merck, PharmaMar, Olema, Polyphor, Immunogen, Plexxikon, Amgen, Akesobio Australia, and Shattuck Labs. SH: equity ownership in Ideal Implant, ROM Tech; research funding/grants from Ambrx, Amgen, AstraZeneca, Arvinas, Bayer, CytomX, Daiichi Sankyo, Dignitana, Genentech/Roche, Gilead, GlaxoSmithKline, Immunomedics, Eli Lilly, Macrogenics, Novartis, Pfizer, Medivation, BioMarin, OBI Pharma, Pieris, PUMA, Radius, Sanofi, Seagen Inc. Zymeworks, and Phoenix Molecular Designs, Ltd.; travel from Lilly. SL: consultancy and advisory board membership with AbbVie, Amgen, AstraZeneca, Bayer Bristol-Myers Squibb, Celgene, Daiichi Sankyo, EirGenix, G1 Therapeutics, GlaxoSmithKline, Gilead, Lilly, Novartis, Pfizer, Pierre Fabre, Prime/Medscape, Puma, Roche/Genentech, Seagen Inc. and Silverback; honoraria from AstraZeneca, Daiichi Sankyo, Novartis, Pfizer, Pierre Fabre, Prime/Medscape, Roche/Genentech, and Samsung; research funding/grants from AbbVie, AstraZeneca, Celgene, Daiichi Sankyo, Gilead, Novartis, Pfizer, Roche/Genentech, and Seagen Inc.; patents/royalties: EP14153692.0, EP21152186.9, EP15702464.7, EP19808852.8, vm Scope GmbH; employee of GBG Forschungs GmbH; other (non-financial – medical writing) with Daiichi Sankyo, Gilead, Novartis, Pfizer, Puma, Roche/Genentech, and Seagen Inc. RM: consultancy with AstraZeneca, Genentech/Roche, Novartis, Puma, and Seagen Inc.; honoraria from AstraZeneca, Genentech, Novartis, Puma, and Seagen Inc.; research funding/grants from AstraZeneca, Daiichi Sankyo, EMD Serono, Genentech/Roche, Pfizer, and Seagen Inc.; travel from Genentech and Seagen Inc. AO: advisory board membership with AstraZeneca, Roche/Genentech, and Seagen Inc.; honoraria from Daiichi Sankyo, Lilly, Pfizer, and Seagen Inc.; research funding/grants from Pfizer and Roche/Genentech; travel from AstraZeneca, Daiichi Sankyo, LEO Pharma, and Lilly. EP: consultancy with Biotheranostics, Mylan Novartis, Pfizer, Puma, and R-pharm; honoraria from Mylan Novartis, Pfizer, Puma, and R-pharm; research funding/grants from AbbVie, Cascadian, Corcept, Genentech, Hoosier Cancer Research Network, Immunogenicity, Merck, Novartis, and Seagen Inc.; speaker's bureau with OncLive Clinical Congress Consultants; travel from Amgen, Genentech, Merck, Novartis, and Tesaro. DC: consultancy with and research funding from Novartis, Roche, and Seagen Inc. LAC: advisory board membership (all uncompensated) from Eisai, Sanofi, Novartis, G1 Therapeutics, Genentech/Roche, GlaxoSmithKline, AZ, Daiichi Sankyo, Aptitude Health, and Exact Sciences; royalty sharing agreement, investorship interest in licensed IP to startup company, Falcon Therapeutics, that is designing neural stem cell-based therapy for glioblastoma multiforme (immediate family member); research funding/grants (to institution) from AbbVie, NanoString, Novartis, Seagen Inc. Syndax, and Veracyte; other (uncompensated relationships) with Aptitude Health, AstraZeneca/Daiichi Sankyo, Exact Sciences, G1 Therapeutics, Genentech/Roche, GlaxoSmithKline, Novartis, and Sanofi. KG: consultancy with AstraZeneca, Ayala, Bristol-Myers Squibb, Genentech, Genomic Health, Gilead, Janssen, Lilly, Merck, Mylan, NanoString, Novartis, Pfizer, and Roche; honoraria from AstraZeneca, Merck Sharp & Dohme, Pfizer, Novartis, and Lilly; research funding/grants from AstraZeneca, Bristol-Myers Squibb, Pfizer, and Roche. GNH: consultancy with, research funding/grants, and travel from Novartis. IK: advisory board membership with AMAG Pharma and Freeline Therapeutics; consultancy with AstraZeneca, Bristol-Myers Squibb, Context Therapeutics, Daiichi Sankyo, Genentech/Roche, Ionis Pharma, Macrogenics, Merck, Novartis, Seagen Inc. and Taiho; employment with AMAG Pharma and Freeline Therapeutics; equity ownership: AMAG Pharma, Freeline Therapeutics, and Vertex; honoraria from AstraZeneca, Celltrion, and Genentech/Roche; research funding/grants from Genentech and Pfizer. SL: consultancy with AbbVie, Amgen, AstraZeneca/MedImmune, Bayer, Bristol-Myers Squibb, Celgene, Daiichi Sankyo, EirGenix, GlaxoSmithKline, Immunomedics, Lilly, Medscape, Merck, Novartis, Pfizer, Pierre Fabre, Puma, Samsung, and Seagen Inc.; honoraria from Chugai Pharma; Patent Pending EP14153692.0; research funding/grants from AbbVie, Amgen, AstraZeneca, Celgene, Daiichi Sankyo, Immunomedics, Myriad Genetics, Novartis, Pfizer, Pierre Fabre, Roche, Seagen Inc. and Vifor Pharma. MP: consultancy and honoraria from Genentech/Roche and Seagen Inc. DS: corporate board membership with BioMarin; consultancy with Lilly, Novartis, Pfizer, and Seagen Inc.; equity ownership in Amgen, BioMarin, Merck Sharp & Dohme, Pfizer, Seagen Inc. Vertex, TORL BioTherapeutics, and 1200 Pharma; honoraria and speaker's bureau from Novartis; research funding/grants from Novartis, Pfizer, and Seagen Inc.; travel from Novartis and Pfizer. JR: employment and equity ownership with Seagen Inc. WF: employment and equity ownership with Seagen Inc. EW: Carrick Therapeutics, G1 Therapeutics, Genentech/Roche, Gilead, GlaxoSmithKline, Jounce, Leap, Lilly, Seagen Inc. Syros Pharma, and Zymeworks; honoraria from Genentech/Roche and Genomic Health; research funding/grants from AstraZeneca and Genentech; other relationship with InfiniteMD. Funding Information: This work was supported by Seagen Inc. (Bothell, WA, USA), the manufacturer of tucatinib and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (no grant number). Writing assistance was funded by Seagen Inc. in accordance with Good Publications Practice guidelines (no grant number). Publisher Copyright: © 2022 The Authors
PY - 2022/3
Y1 - 2022/3
N2 - Background: In the primary analysis of the HER2CLIMB trial, tucatinib added to trastuzumab and capecitabine significantly improved overall survival (OS) and progression-free survival (PFS) in patients with human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer. We report efficacy and safety outcomes, including the final OS and safety outcomes from follow-up in HER2CLIMB. Patients and methods: HER2CLIMB is a randomized, double-blind, placebo-controlled trial in patients with locally advanced or metastatic HER2+ breast cancer, including patients with brain metastases. Patients were randomized 2 : 1 to receive tucatinib or placebo, in combination with trastuzumab and capecitabine. After the primary analysis (median follow-up of 14 months), the protocol was amended to allow for unblinding sites to treatment assignment and cross-over from the placebo combination to the tucatinib combination. Protocol prespecified descriptive analyses of OS, PFS (by investigator assessment), and safety were carried out at ∼2 years from the last patient randomized. Results: Six hundred and twelve patients enrolled in the HER2CLIMB trial. At a median OS follow-up of 29.6 months, median duration of OS was 24.7 months for the tucatinib combination group versus 19.2 months for the placebo combination group [hazard ratio (HR) for death: 0.73, 95% confidence interval (CI): 0.59-0.90, P = 0.004] and OS at 2 years was 51% and 40%, respectively. HRs for OS across prespecified subgroups were consistent with the HR for the overall study population. Median duration of PFS was 7.6 months for the tucatinib combination group versus 4.9 months for the placebo combination group (HR for progression or death: 0.57, 95% CI: 0.47-0.70, P < 0.00001) and PFS at 1 year was 29% and 14%, respectively. The tucatinib combination was well tolerated with a low rate of discontinuation due to adverse events. Conclusions: With additional follow-up, the tucatinib combination provided a clinically meaningful survival benefit for patients with HER2+ metastatic breast cancer.
AB - Background: In the primary analysis of the HER2CLIMB trial, tucatinib added to trastuzumab and capecitabine significantly improved overall survival (OS) and progression-free survival (PFS) in patients with human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer. We report efficacy and safety outcomes, including the final OS and safety outcomes from follow-up in HER2CLIMB. Patients and methods: HER2CLIMB is a randomized, double-blind, placebo-controlled trial in patients with locally advanced or metastatic HER2+ breast cancer, including patients with brain metastases. Patients were randomized 2 : 1 to receive tucatinib or placebo, in combination with trastuzumab and capecitabine. After the primary analysis (median follow-up of 14 months), the protocol was amended to allow for unblinding sites to treatment assignment and cross-over from the placebo combination to the tucatinib combination. Protocol prespecified descriptive analyses of OS, PFS (by investigator assessment), and safety were carried out at ∼2 years from the last patient randomized. Results: Six hundred and twelve patients enrolled in the HER2CLIMB trial. At a median OS follow-up of 29.6 months, median duration of OS was 24.7 months for the tucatinib combination group versus 19.2 months for the placebo combination group [hazard ratio (HR) for death: 0.73, 95% confidence interval (CI): 0.59-0.90, P = 0.004] and OS at 2 years was 51% and 40%, respectively. HRs for OS across prespecified subgroups were consistent with the HR for the overall study population. Median duration of PFS was 7.6 months for the tucatinib combination group versus 4.9 months for the placebo combination group (HR for progression or death: 0.57, 95% CI: 0.47-0.70, P < 0.00001) and PFS at 1 year was 29% and 14%, respectively. The tucatinib combination was well tolerated with a low rate of discontinuation due to adverse events. Conclusions: With additional follow-up, the tucatinib combination provided a clinically meaningful survival benefit for patients with HER2+ metastatic breast cancer.
KW - brain metastases
KW - capecitabine
KW - human epidermal growth factor receptor 2-positive (HER2)
KW - metastatic breast cancer
KW - trastuzumab
KW - tucatinib
UR - http://www.scopus.com/inward/record.url?scp=85123294615&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85123294615&partnerID=8YFLogxK
U2 - 10.1016/j.annonc.2021.12.005
DO - 10.1016/j.annonc.2021.12.005
M3 - Article
C2 - 34954044
AN - SCOPUS:85123294615
SN - 0923-7534
VL - 33
SP - 321
EP - 329
JO - Annals of Oncology
JF - Annals of Oncology
IS - 3
ER -